BACKGROUND: The COMBINE study evaluated the effects of acamprosate, naltrexone, and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes and moderate treatment response. METHODS: We analyzed daily indicators of any drinking in 90 days prior to randomization using a trajectory-based approach. General linear models and generalized logistic regression assessed main and interactive effects of prerandomization drinking trajectories and treatment on summary drinking measures during active treatment. RESULTS: We identified five trajectories of any drinking prior to randomization: "T1: frequent drinkers", "T2: very frequent drinkers", "T3: nearly daily drinkers", "T4: consistent daily drinkers", and "T5: daily drinkers stopping early". During treatment, "T3: nearly daily drinkers" and "T4: consistent daily drinkers" had significantly worse drinking outcomes than "T1: frequent drinkers", while "T5: daily drinkers stopping early" had comparable drinking outcomes to "T1: frequent drinkers". Acamprosate significantly increased the chance of abstinence from heavy drinking for the "T2: very frequent drinking" trajectory but decreased the chance of abstinence from heavy drinking for "T5: daily drinkers stopping early". Naltrexone differentially improved rates of continuous abstinence for very frequent drinkers. CONCLUSIONS:Acamprosate benefited very frequent drinkers and contrary to expectations was associated with poorer response compared to placebo for consistent daily drinkers who had longer durations of pretreatment abstinence (e.g., ≥14 days). Baseline drinking trajectories also moderated naltrexone effects. These findings may help clinicians identify patients for whom acamprosate and naltrexone may be most beneficial.
RCT Entities:
BACKGROUND: The COMBINE study evaluated the effects of acamprosate, naltrexone, and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes and moderate treatment response. METHODS: We analyzed daily indicators of any drinking in 90 days prior to randomization using a trajectory-based approach. General linear models and generalized logistic regression assessed main and interactive effects of prerandomization drinking trajectories and treatment on summary drinking measures during active treatment. RESULTS: We identified five trajectories of any drinking prior to randomization: "T1: frequent drinkers", "T2: very frequent drinkers", "T3: nearly daily drinkers", "T4: consistent daily drinkers", and "T5: daily drinkers stopping early". During treatment, "T3: nearly daily drinkers" and "T4: consistent daily drinkers" had significantly worse drinking outcomes than "T1: frequent drinkers", while "T5: daily drinkers stopping early" had comparable drinking outcomes to "T1: frequent drinkers". Acamprosate significantly increased the chance of abstinence from heavy drinking for the "T2: very frequent drinking" trajectory but decreased the chance of abstinence from heavy drinking for "T5: daily drinkers stopping early". Naltrexone differentially improved rates of continuous abstinence for very frequent drinkers. CONCLUSIONS:Acamprosate benefited very frequent drinkers and contrary to expectations was associated with poorer response compared to placebo for consistent daily drinkers who had longer durations of pretreatment abstinence (e.g., ≥14 days). Baseline drinking trajectories also moderated naltrexone effects. These findings may help clinicians identify patients for whom acamprosate and naltrexone may be most beneficial.
Authors: Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis Journal: J Clin Psychopharmacol Date: 2006-12 Impact factor: 3.153
Authors: Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler Journal: J Clin Psychopharmacol Date: 2007-10 Impact factor: 3.153
Authors: J P Lhuintre; N Moore; G Tran; L Steru; S Langrenon; M Daoust; P Parot; P Ladure; C Libert; F Boismare Journal: Alcohol Alcohol Date: 1990 Impact factor: 2.826
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Stephanie S O'Malley; Robert W Robin; Aryeh L Levenson; Iva GreyWolf; Lawrence E Chance; Colin A Hodgkinson; Denise Romano; Jane Robinson; Boris Meandzija; Verner Stillner; Ran Wu; David Goldman Journal: Alcohol Clin Exp Res Date: 2008-07 Impact factor: 3.455
Authors: Kyle M Kampman; Helen M Pettinati; Kevin G Lynch; Hu Xie; Charles Dackis; David W Oslin; Thorne Sparkman; Tiffany Sharkoski; Charles P O'Brien Journal: Addict Behav Date: 2009-03-24 Impact factor: 3.913
Authors: Karl Mann; Stephanie S O'Malley; Ralitza Gueorguieva; Ran Wu; Patrick G O'Connor; Constance Weisner; Lisa M Fucito; Sabine Hoffmann Journal: Alcohol Clin Exp Res Date: 2014-10 Impact factor: 3.455
Authors: Ralitza Gueorguieva; Ran Wu; Wan-Min Tsai; Patrick G O'Connor; Lisa Fucito; Heping Zhang; Stephanie S O'Malley Journal: Eur Neuropsychopharmacol Date: 2015-06-20 Impact factor: 4.600
Authors: Ralitza Gueorguieva; Ran Wu; Dennis Donovan; Bruce James Rounsaville; David Couper; John Harrison Krystal; Stephanie Samples O'Malley Journal: Alcohol Date: 2011-09-17 Impact factor: 2.405
Authors: Bruno Scherrer; Julien Guiraud; Giovanni Addolorato; Henri-Jean Aubin; Andrea de Bejczy; Amine Benyamina; Wim van den Brink; Fabio Caputo; Maurice Dematteis; Anna E Goudriaan; Antoni Gual; Falk Kiefer; Lorenzo Leggio; Otto-Michael Lesch; Icro Maremmani; David J Nutt; François Paille; Pascal Perney; Roch Poulnais; Quentin Raffaillac; Jürgen Rehm; Benjamin Rolland; Nicolas Simon; Bo Söderpalm; Wolfgang H Sommer; Henriette Walter; Rainer Spanagel Journal: Alcohol Clin Exp Res Date: 2021-08-21 Impact factor: 3.928
Authors: Kenneth Blum; Bruce Steinberg; Marjorie C Gondre-Lewis; David Baron; Edward J Modestino; Rajendra D Badgaiyan; B William Downs; Debasis Bagchi; Raymond Brewer; Thomas McLaughlin; Abdalla Bowirrat; Mark Gold Journal: Psychol Res Behav Manag Date: 2021-12-17